PROGRAM – IN PROGRESS

2020 EDUCATIONAL PROGRAM SERIES

Virtual, Live, Interactive, Flexible

June – October, 2020

2

2020 EDUCATION PROGRAM SERIES

Table ContentsWelcome .................................................................................................................... 4

Registration ................................................................................................................ 5

Program-at-a-Glance .................................................................................................... 6

June .................................................................................................................................. 8

July ................................................................................................................................... 8

August .............................................................................................................................10

September .......................................................................................................................12

October ...........................................................................................................................13

Contributed Paper Sessions ..........................................................................................14

[ALIQUOT NUMBER: 5]

[TEST RESULTS]WBC 4.5 10^3uL 3.0 - 12.1RBC 4.05 10^6uL 4.10 - 5.80Hgb 15.9 g/dL 12.7 - 17.1MCV 79 fL 78.1 - 99.2MCH 28.9 pg 25.7 - 33.8MCHC 32 g/dL 32.0 - 35.3RDW 12.2 % 11.8 - 15.3

[STUDY NAME: MH303]

[Freezerworks ID: 100032]

CREATION DATE:04/16/2020[ ]

[ALIQUOT STATUS: Checked Out]

[ALIQUOT NUMBER: 5]

[TEST RESULTS]WBC 4.5 10^3uL 3.0 - 12.1RBC 4.05 10^6uL 4.10 - 5.80Hgb 15.9 g/dL 12.7 - 17.1MCV 79 fL 78.1 - 99.2MCH 28.9 pg 25.7 - 33.8MCHC 32 g/dL 32.0 - 35.3RDW 12.2 % 11.8 - 15.3

[ALIQUOT STATUS: Checked Out]

[STUDY NAME: MH303]

[Freezerworks ID: 100032]

CREATION DATE:04/16/2020[ ]

Sample the DifferenceClick

4

2020 EDUCATION PROGRAM SERIES

WelcomeDear biobanking community,

On behalf of ISBER’s Board of Directors, we welcome you to the ISBER 2020 Educational Program Series.

Biobanks create the promise for unlocking biological processes, creating knowledge and promoting a better tomorrow. As research is dependent on biospecimens, biobanks have become the bedrock to accelerating scientific discoveries through robust and standardized tissue handling specialties. Stemming from the success stories is a blueprint that places the biobank community at the forefront of research infrastructure for many generations to come.

Global leaders were set to converge in Anaheim, California during the month of April, 2020 at the largest international biobank conference, the ISBER 2020 Annual Meeting & Exhibits, to address the impact of biobanks on science and how the related discoveries are establishing a roadmap to extend our knowledge network. Unfortunately, the ISBER 2020 Annual Meeting & Exhibits was cancelled as a result of the SARS-COV-2 (COVID-19) pandemic.

As a result of the cancelation of the Annual meeting, ISBER has developed the ISBER 2020 Educational Program Series which will be presented throughout the summer and Fall of 2020. The goal of this series is to provide much of the educational content from the ISBER 2020 Annual Meeting virtually to our members. We are excited that this series incorporates a large proportion of the invited speakers and abstract presenters scheduled to present in Anaheim, though it does not include every scheduled speaker and session.

Furthermore, please note that the schedule is continuing to develop. We will continue to add speakers and firm up session dates. It is very important to us that we remain flexible and cognizant to the needs of both our speakers and our attendees during this time of uncertainty and ever changing priorities. We thank you for joining us for the ISBER 2020 Educational Program Series. If you are unable to attend a live session, please know that the recordings will be available to you post-event.

If you have any questions, please reach out to us at info@isber.org.

Best regards,

Debra GarciaISBER President 2019-2020

Dan CatchpooleISBER President 2020-2021

5

2020 EDUCATION PROGRAM SERIES

Registration

Registration ISBER Member Non-Member

Full Educational Series* $200 $350

Full Educational Series* – Student/Technician

$120 $210

Single Webinar $50 $75

Corporate Session Free Free

Workshops, Contributed Paper Sessions, and Round Table Discussions

Only accessible to individuals registered for the full educational series.

*Purchase of the full educational series gives you access to all live events (including webinars, workshops, contributed paper sessions, and round table discussions) as well as recordings of all events.

REGISTER NOW

Prefer to register for individual sessions?

Click on the links in the program-at-a-glance.

Low and Middle Income Countries (LMICs):Delegates in countries identified by the World Bank as Low and Lower-Middle Income are eligible for a 50% discount on meeting registration. Delegates in countries identified as Upper-Middle Income are eligible for a 25% discount on meeting registration. If you are eligible to receive a discount please contact info@isber.org.

To confirm the income classification for your country, please click here.

Please note that if you are also a technician or student, you will receive only the LMIC discount or the technician/student discount, whichever is higher.

6

2020 EDUCATION PROGRAM SERIES

Program-at-a-GlanceCHECK YOUR TIME ZONE

Times listed in this program: Pacific Time (PT) • Eastern Time (ET) • Central European Time (CET) • China Standard Time (CST)

Click on the session title to be taken to the session details.

June, 2020

June 247am PT/10am ET/

4pm CET/10pm CST

SPONSORED: MONITORING NUCLEIC ACID INTEGRITY DURING LONG-TERM STORAGE WITH AUTOMATED ELECTROPHORESISThis session is hosted by Agilent TechnologiesPresented by: Elisa Viering (Agilent Technologies, Germany) and Monique Albert (Ontario Biobank, Canada)

July, 2020

July 8 9am PT/

12pm ET/ 6pm CET/

12am next day CST

WORKSHOP: NEGLECTED ETHICS IN BIOBANKING: ADDRESSING ISSUES OF SUSTAINABILITY, UTILIZATION, AND STEWARDSHIP*Presented by: Aaron J. Goldenberg (Case Western University, USA), Kyle Brothers (University of Louisville, USA), Jean Cadigan (University of North Carolina, USA)

July 1610am PT/

1pm ET/7pm CET/ 1am next day CST

BIOSPECIMENS FOR ACCELERATING BIOMARKER DISCOVERY TO ADVANCE DIAGNOSIS AND THERAPEUTICSPresented by: Ida Biunno (ISENET Biobanking, Italy), Stephen Lin (California Institute for Regenerative Medicine, USA), Lauren Leiman (BloodPAC, USA), Jerry Lee (University of Southern California, USA), Meri Firpo (Memphis Meats, USA)

July 229am PT/

12pm ET/ 6pm CET/

12am next day CST

SPONSORED: A PATH TOWARDS SUSTAINABILITY - ISO 20387 ACCREDITATION OF A CORNELL BIOBANKThis session is hosted by Brooks Life SciencesPresented by: Lara Mouttham (Cornell University, USA), Susan J. Garrison (Cornell University, USA), and David Lewandowski (Brooks Life Sciences, USA)

August, 2020

August 55pm PT/ 8pm ET/

2am CET NEXT DAY/ 8am CST NEXT DAY

CONTRIBUTED PAPER SESSION*Presented by: Chad Borges (Arizona State University, USA), Amanda Rush (University of Sydney, Australia), Charles W. Wang (Shanghai Xinhua Hospital, China), Carmen Quinn (University of New South Wales, Australia)

Accessible to full series registrants

August 126am PT/9am ET/

3pm CET/9pm CST

GLOBAL BIOBANK EXPERIENCES: NAVIGATING YOUR BIOREPOSITORY OPERATIONSPresented by: Yunice Shao (China National GeneBank, China), Iman Farahat (Egyptian National Cancer Institute, Egypt)

*Workshops and Contibuted Paper Sessions are only available to individuals registered for the full series.

7

2020 EDUCATION PROGRAM SERIES

*Workshops and Contibuted Paper Sessions are only available to individuals registered for the full series.

Additional sessions will be added to the schedule as they are confirmed.

Program-at-a-GlanceCHECK YOUR TIME ZONE

Times listed in this program: Pacific Time (PT) • Eastern Time (ET) • Central European Time (CET) • China Standard Time (CST)

Click on the session title to be taken to the session details.

August, 2020

August 198am PT/11am ET/

5pm CET/ 11pm CST

PRACTICAL APPLICATIONS FOR BIOREPOSITORY PROCESSESPresented by: Umesh Bhanot (Memorial Sloan Kettering Cancer Center, USA), Steven Haynes (Sheffield University Medical School, UK)

August 267am PT/

10am ET/ 4pm CET/10pm CST

SPONSORED: 5,000 DAYS OF BIOBANK EXPERIENCE - WHAT HAVE WE LEARNED AND HOW DO WE PREPARE FOR THE NEXT DECADE?This session is hosted by Thermo Fisher Presented by: Erik Steinfelder (Thermo Fisher Scientific, The Netherlands)

REGISTER

September, 2020

September 99am PT/

12pm ET/ 6pm CET/

12am next day CST

SPONSORED: THE IMPORTANCE OF SAMPLE MANAGEMENT IN PRECISION MEDICINE: A HIGH-THROUGHPUT BIOBANKING WORKFLOW SOLUTIONThis webinar is hosted by PerkinElmer Presented by: Andrew Brooks (RUCDR, Brooks Life Sciences, USA)

REGISTER

September 239am PT/

12pm ET/ 6pm CET/

12am next day CST

HOW BIOBANKS ARE PAVING A PATH TO A BETTER TOMORROW Presented by: Kyle Van Houtan (Monterey Bay Aquarium, USA), Lester Russell (National Health Service, UK), Dawn Barry (LunaPBC, USA)

REGISTER

Exact Date TBD CONTRIBUTED PAPER SESSION Accessible to full series registrants

October, 2020

Exact Date TBDFROM HUMAN TUMOR BIOBANKING TO HUMAN TUMOR 3D-BIOPRINTING: INNOVATING FOR PERSONALIZED MEDICINE IN ONCOLOGYPresented by: Nicolas Forraz (CTIBiotech, France)

REGISTRATION COMING SOON

Exact Date TBD

MOVING SCIENCE FORWARD - RESULTS DRIVE VALUE/REPUTATION OF BIOBANKS AND ENHANCE SUSTAINABILITYPresented by: Christopher Loffredo (Georgetown University Medical Center, USA), Anderson Mayfield (NOAA/University of Miami, USA), Antonio Hugo Campos (Rede D’Or Network Hospitals, Brazil)

REGISTRATION COMING SOON

Exact Date TBD CONTRIBUTED PAPER SESSION Accessible to full series registrants

8

2020 EDUCATION PROGRAM SERIES

JUNESPONSORED: MONITORING NUCLEIC ACID INTEGRITY DURING LONG-TERM STORAGE WITH AUTOMATED ELECTROPHORESIS

June 24 at 7am PT/10am ET/4pm CEST (Europe)/ 10pm CST (China)/11pm JST

This session is hosted by Agilent Technologies

The DNA and RNA samples that you store in your biobank will be used for important research later. Our webinar will show you how to improve confidence in your sample quality, before and after samples go into storage using different automated electrophoresis platforms. In the webinar, we will have two retro-spective analysis of sample storage conditions. Agilent’s nucleic acid QC portfolio streamlines the analysis of both DNA and RNA, including high-molecular weight genomic DNA through 165 kb. Each of Agilent’s automated electrophoresis instruments supply digital data with objective quality metrics that allows for easy data archiving and comparisons. Through the routine use of quality control, biobanks can evaluate past and current procedures for continuous improvement while also providing biobank users a detailed understanding of sample quality.

This session will include the following talks:

OBJECTIVE ANALYSIS OF DNA AND RNA SAMPLES WITH QUALITY METRICS

Elisa Viering, MSc, Agilent Technologies, Germany

RNA AND DNA INTEGRITY REMAIN STABLE AFTER LONG TERM CRYOGENIC STORAGE

Monique Albert PhD, Ontario Biobank, Canada

JULYWORKSHOP: NEGLECTED ETHICS IN BIOBANKING: ADDRESSING ISSUES OF SUSTAINABILITY, UTILIZATION, AND STEWARDSHIP

July 8 at 9am PT/12pm ET/6pm CET (Europe)/ 12am next day CST (China)/1am next day JST

Aaron J. Goldenberg, Case Western University, USA, Kyle Brothers, University of Louisville, USA, Jean Cadigan, University of North Carolina, USA

The promotion of precision medicine has led to increased inter-est in larger collections of biospecimens that are more represen-tative of genetic variation across and within populations. There is now a robust literature identifying and addressing the ethical, legal, and social implications of biobanking. Nevertheless, the recent evolution of biobank networks has revealed a number of unanswered and understudied questions regarding stewardship and utilization of biospecimens and data, including:

1. The discrepancy between limited funding and the assumption that the biobank will last “permanently;”

2. The lack of planning for what will happen to the specimens and data if the bank terminates; and

3. Underutilization of specimens and data. Since that time, the biobanking industry has grown more complex, with increasing numbers of biobanks forming networks.

In theory, these networks should facilitate increased stability of operations and utilization. This presentation will review the re-sults from a study that investigated to what extent, if any, current U.S. networked biobanks seem to be achieving increased sta-bility and utilization. In 2018-19, we conducted interviews with 37 representatives from networked biobanks. Questions elicited descriptions of the genesis of the network, the challenges and benefits of networking, the utilization process of specimens and data, and the funding sources. We analyzed transcripts to ascer-tain how the three concerns highlighted in our prior research on biobanks play out in the context of networked biobanks. Preliminary results reveal that biobank networks have a range of ways of addressing sustainability and utilization with mixed results. Although networking of biobanks ought to increase the stability and utilization of biobank resources, networks still struggle with these goals. We will use our results to offer recom-mendations to consider. We will also discuss the implications of our findings as they relate to ensuring public trust in networked biobanking. Finally, we will give ISBER members the opportunity to reflect on the creation of models of stewardship that honor

9

2020 EDUCATION PROGRAM SERIES

donor’s desire to see their samples and data used for health research at a time when many biobanks struggle with underutili-zation by researchers.

BIOSPECIMENS FOR ACCELERATING BIOMARKER DISCOVERY TO ADVANCE DIAGNOSIS AND THERAPEUTICS

July 16 at 10am PT/1pm ET/7pm CEST (Europe)/ 1am next day CST (China)/2am next day JST

Advancing personalised medicine will require new and effective biomarkers that will aid in early and better diagnosis and the development of efficient new therapies. The hallmark of such advances lies in successful translational research which utilizes human biospecimens. Breakthrough discoveries will therefore require quality biospecimens for the identification, development and validation of new research findings.

This session represents a review of biobanking of novel human cell systems for a new generation of cellular therapies and per-sonalised diagnostic testing. Speakers will address the new chal-lenges that these systems bring for biobanks in terms of ethics, data management, preservation technology, quality control and characterisation. They will also present potential new technolo-gies and thinking that will be needed to meet these challenges.

BIOSPECIMENS TO PROFILE HUMAN DISEASES

Ida Biunno, ISENET Biobanking, Italy

A disease reflects perturbations in the cellular components work-ing within complex intracellular and intercellular networks. To better dissect the human interactome more accurate biomarkers are required in addition to more sophisticated tools to monitor the functional integrity of the network perturbed by disease. High resolution “omics“ screenings of populations enrolled in large scale observational and clinical trials, in addition to novel and more performing technological platforms, (e.g. RNA seq, and single cell analysis, stem cells and organdies) can monitor more accurately the molecular relationship between different patho-biological processes.

CREATION OF THE CIRM IPSC COLLECTION FOR DISEASE MODELING AND DRUG SCREENING

Stephen Lin, California Institute for Regenerative Medicine, USA

The mission of the California Institute for Regenerative Medicine (CIRM) is to accelerate stem cell treatments to patients with unmet medical needs. Starting with $3 billion, CIRM has funded over

1,000 programs and 60 clinical trials in cell and gene medicine. In support of its mission, CIRM has established several resources for research and translational development. CIRM created an in-duced pluripotent stem cell (iPSC) repository maintained by the FUJIFILM Cellular Dynamics that is currently the largest publicly accessible pluripotent stem cell bank in the world with 2774 lines created. The iPSC Repository is a product of CIRM’s Human iPSC Initiative, a coordinated multi-year effort launched in 2013 to collect tissue samples, create iPSC lines, and build infrastructure to bank and distribute those lines. The tissue collection initiative consisted of 13 programs covering over 8 disease classes and 20 diagnoses, with diagnosis matched control samples for each of the disorders. All donor consent forms followed guidelines set by CIRM and approved by Institutional Review Boards (IRBs). Demographic information plus clinical histories and diagnoses were reported by donors and clinics through questionnaires created for each disease collection. All tissue samples were sent to one iPSC derivation site in California operated by FCDI in order to produce a uniform iPSC collection using a single reprogramming methodology (using episomal vectors) and consistent validation assays. iPSC cell banks for distribution were generated at passage 10 for the vast majority of the collection. All distribution lines passed quality control standards for identity, pluripotency, karyotype, and sterility. Commercial license terms were negotiated at the onset of the banking initiative, allowing repository lines to be used by both non-profit and for-profit enti-ties for both academic and commercial use. The CIRM Repository has been utilized by many groups worldwide for a wide variety of both research and drug discovery purposes. CIRM and FCDI are committed to continually improve the collection as a resource for the scientific community.

BLOOD PROFILING ATLAS IN CANCER (BLOODPAC) CONSORTIUM: RAISING THE BAR FOR LBX DATA IN PUBLIC DATABASES

Lauren Leiman, BloodPAC, USA, Jerry Lee, University of Southern California, USA

The Blood Profiling Atlas in Cancer (BloodPAC) is a consortium of over 35 stakeholders in the liquid biopsy field representing government (e.g. U.S. Food and Drug Administration, National Cancer Institute, Veterans Health Administration), professional societies and non-profits (e.g. American Association for Cancer Research, College of American Pathologists), academic, and for profit (biotechnology, diagnostic and pharmaceutical compa-nies) collaborating to accelerate the development and validation of liquid biopsy assays to improve the outcomes of patients with cancer. This presentation will cover a brief history of BloodPAC and describe ongoing efforts to develop standards and best practices to collect preanalytical variables within the BloodPAC

10

2020 EDUCATION PROGRAM SERIES

AUGUSTCONTRIBUTED PAPER SESSION 1

August 5 at 5pm PT/8pm ET/2am CET Next Day/ 8am CST Next Day/10am AEST Next Day

BIOCHEMICALLY TRACKED VARIABILITY OF BLOOD PLASMA THAWED-STATE EXPOSURE TIMES IN A MULTISITE COLLECTION STUDY

Presenter: Chad R Borges, Arizona State University, United StatesCategory: Biospecimen Research and Science

AN ECONOMIC ANALYSIS OF CANCER BIOBANKS IN NEW SOUTH WALES

Presenter: Amanda Rush, University of Sydney, AustraliaCategory: Repository Management

ANALYSIS OF SAMPLE INTEGRITY FOR DEVELOPING A “VALUE STATEMENT” OF SAMPLES AND BIOBANK IN CHINA

Presenter: Charles W. Wang, Shanghai Xinhua Hospital, ChinaCategory: Hot Topics

MOVING WITH THE TIMES: THE HEALTH SCIENCE ALLIANCE BIOBANK PATHWAY TO SUSTAINABILITY

Presenter: Carmen Quinn, University of New South Wales, AustraliaCategory: Biobanking Profiles

GLOBAL BIOBANK EXPERIENCES: NAVIGATING YOUR BIOREPOSITORY OPERATIONS

August 12 at 6am PT/9am ET/3pm CEST/ 9pm CST (China)/10pm JST

Successful repository operations with a solid base in the imple-mentation of best practices are universal and can be scaled for implementation in any size operation. This session will highlight proven, successful repository operations across the globe. Presentations will demonstrate how repositories stayed relevant and developed coordinated activities to tackle challenges and the changing demands of the scientific communities they serve.

Data Commons to facilitate cross analysis and improve the usability and reliability of the data for liquid biopsy research.

THE INTERNATIONAL STEM CELL BANKING INITIATIVE: BUILDING CONSENSUS

Meri Firpo, Memphis Meats, USA

Description coming soon.

SPONSORED: A PATH TOWARDS SUSTAINABILITY – ISO 20387 ACCREDITATION OF A CORNELL BIOBANK

July 22 at 9am PT/12pm ET/6pm CEST/ 12am next day CST/1am JST

This session is hosted by Brooks Life Sciences

Presented by: Lara Mouttham (Cornell University, USA), Susan J. Garrison (Cornell University, USA), and David Lewandowski (Brooks Life Sciences, USA)

Biobanks play an integral role in research and precision medicine by collecting, processing, storing, and distributing high-quality biological material and associated data. With large commit-ments from the institutions that support biobanks – the NCI has reported spending over 50 million dollars per year on its biobank infrastructure - and advancements in precision medicine resulting directly from these resources, stakeholders (donors, funders, and users) are more likely to request a value and impact measure for the biobanks they support, along with a long-term sustainability plan that can assure the continuous running of such operations beyond the immediate future.

In January 2019, the American Association of Laboratory Accreditation (A2LA) introduced the ISO 20387 Biobank Accreditation Program. This third party accreditation offered an independent review of an organization’s compliance with ISO 20387 - General Requirements for Biobanking, the first standard released by the International Organization for Standardization (ISO) exclusively for biobanks. In this workshop we will explore how accreditation to ISO 20387 can improve biobank sustain-ability, by using the case example of the first biobank in the world to receive accreditation to this standard - the Cornell Veterinary Biobank.

11

2020 EDUCATION PROGRAM SERIES

CNGB’S APPROACH TO SUPPORT SHARING OF SAMPLE DATA

Yunice Shao, China National GeneBank, China

The China National GeneBank (CNGB) is a national gene bank integrating a large-scale biorepository, an omics database, a sequencing platform and a gene synthesis platform. CNGB has opened its public service platform to government, research institutions, universities, hospitals, and biotechnology compa-nies, to facilitate life science research projects based on its ability to store, read, and write massive biological resources.

Its data platform, the China National GeneBank DataBase (CNGBdb), is built for biological data sharing and application. Based on big data and cloud computing technologies, the platform provides data services such as archive, search, analysis, data man-agement and scientific databases to researchers around the world. Covering various research fields, the massive scientific data system supports different data types and multi-dimensional analysis.

The presentation will highlight how the integrated infrastructure has been used to facilitate multiple high-impact collaborations and CNGB’s approach to support sharing and use of sample data.

EVIDENCE-BASED BIOBANKING IN THE INTERFACE BETWEEN TRANSLATIONAL CANCER RESEARCH AND DIAGNOSTICS: EXPERIENCE FROM EGYPTIAN CANCER INSTITUTE

Iman Farahat, Egyptian National Cancer Institute, Egypt

Value-based personalised cancer care focus on molecular pro-file-based treatment decisions. Biobanks facilitate clinical trials research on biomarker-integrated approach for cancer treat-ment. The Egyptian National Cancer Institute (ENCI) biobank was established in 2016 to promote standardized collection of cancer tissue exceeding the requirement of cancer diagnosis for the conduction of translational research. Biobanks offer the advantage of beforehand collection of tissue and as much com-plete relevant clinical data. Biobanking practice helped reduce the quality gap between routine collection of specimens and biospecimen collection for precision medicine. Preanalytical variables are monitored for the isolation of intracellular parti-cles such as DNA, RNA and proteins. The implementation of evidence-based international standards in the operation of biobanks, including the use of standard operating procedures for biospecimen handling, promotes biospecimens quality to meet the requirements of precision medicine. Supporting infrastructure in cancer biobanks and integrated pathology services including biobanking staff working alongside molecular pathology teams represent a suitable interface between cancer research and diagnostics.

PRACTICAL APPLICATIONS FOR BIOREPOSITORY PROCESSES

August 19 at 8am PT/11am ET/5pm CEST (Europe)/ 11pm CST (China)/12am next day JST

Biobanks have been portrayed as having the promise to unlock biological processes and promote a better tomorrow. Following the advent of the human genome project, biobanks have become the bedrock to accelerating scientific discoveries. Stemming from the success stories is a blueprint that places the biobank community at the forefront of research infrastructure for many generations to come. Discussions will include utilization of the methods and technology that support acquisition, data annotation, processing, quality control, cryopreservation, and cold-chain logistics.

DIGITAL PATHOLOGY TOOLS: ENHANCING COLLECTION, QA AND RESEARCH

Umesh Bhanot, Memorial Sloan Kettering Cancer Center, USA

RESOLVING TECHNICAL AND DATA MANAGEMENT CHALLENGES WITH DISPARATE HISTORIC SAMPLE COLLECTIONS

Steven Haynes, Sheffield University Medical School, UK

The University of Sheffield Biorepository has been fully op-erational since 2010, fulfilling a remit established to provide well-characterised, human tissue for research projects stored under Human Tissue regulations (HTA). The focus of the biore-pository is storage and retrieval of human tissues for research into human metabolism, cardiovascular disease and neurological disorders. Specimens are arranged into either current active research projects or those committed into discreet biobanks; primarily, the Sheffield Brain Bank, Cardiovascular Bank and the Musculoskeletal Bone Bank. Historic collections extend back 20 years prior to establishment of the biorepository. Current samples are collected both through primary investigators at the Medical School and groups of external researchers possessing validated ethics. Human Tissue Authority compliant storage is complex and labour intensive. Over a hundred research projects have utilised our biorepository service during the past decade; in excess of 600,000 samples have been stored. A high proportion of these are frozen samples (75%) with the remainder kept at room temperature, or under liquid nitrogen. We discuss assembling these discrete collections using robust data manage-ment and improved governance processes to combat technical challenges.

12

2020 EDUCATION PROGRAM SERIES

SPONSORED: 5,000 DAYS OF BIOBANK EXPERIENCE – WHAT HAVE WE LEARNED AND HOW DO WE PREPARE FOR THE NEXT DECADE?

August 26 at 7am PT/10am ET/4pm CET (Europe)/ 10pm CST (China)/11pm JST

This session is hosted by Thermo Fisher Scientific

Erik Steinfelder, Thermo Fisher Scientific, The Netherlands

Last year, a study performed by the German Biobank Node (GBN) proved again that researchers are in need of high-quality samples that have been processed and stored under reliable conditions. While this might seem obvious, it is easier said than done for many biobankers. What is the best way to prepare and store samples if you are focusing on specific molecular mechanisms of diseases versus investigation of target expression in large patient cohorts when designing a clinical trial? Before samples are actually stored, it is good to have a clear under-standing of their potential use i.e. which analytical technologies will be used. In those cases where the analytical end goal is not clear, consensus should be there on which general storage conditions must apply. In the last decade, hundreds of biobanks around the globe were supported by our cold storage solutions, pre-analytical workflows and -omics technologies. What did we see, learn, develop and improve that could help you achieve the requirements of researchers that are desperately looking for samples and associated clinical data? Join us for an industry perspective presented in an interactive manner that could help you to optimize your approach and processes.

SEPTEMBERSPONSORED: THE IMPORTANCE OF SAMPLE MANAGEMENT IN PRECISION MEDICINE: A HIGH-THROUGHPUT BIOBANKING WORKFLOW SOLUTION

September 9 at 9am PT/12pm ET/6pm CEST/ 12am next day CST/1am JST

This webinar is hosted by PerkinElmer

Andrew Brooks, RUCDR, Brooks Life Sciences, USA

The increased acceptance and implementation of precision medicine, direct to consumer genomics and applications such as regenerative medicine have driven the need and adoption for the storage of primary samples and the isolation and storage of high quality, high molecular weight nucleic acid. One reason for primary sample and nucleic acid storage is the value of the information held within the sample.

The application of sequencing technologies to research and clin-ical settings has increased dramatically, generating vast amounts of data about variations in our genomes that could explain some differences in disease susceptibility, progression and how pa-tients react to drugs. The move towards precision medicine and immune modulation therapy development both requiring se-quencing in the treatment workflow drive the demand for faster processing, storage and data sample management techniques.

Efficient and effective storage ensuring sample integrity is of the utmost importance; retention of sample information with the as-sociated phenotypic insight can provide a wealth of genetic and environmental information that can be unlocked in an attempt to better understand disease and health. In this workshop we explore industry collaborations to provide a solution to the in-creased need for efficient sample management and nucleic acid extraction that meet todays increased requirement for higher throughput full workflow solutions.

HOW BIOBANKS ARE PAVING A PATH TO A BETTER TOMORROW

September 23 at 9am PT/12pm ET/6pm CEST/ 12am next day CST/1am JST

Research technologies are transforming our biological knowl-edge-base in ways that have never been possible. As the stewards of quality biospecimens and associated big data,

13

2020 EDUCATION PROGRAM SERIES

biobanks are providing pathways to diagnostics and discovery that permeate across the globe with the goal of improvement in prevention, wellness, and healthcare applications. The opening plenary of ISBER 2020 aims to provide high-impact scientific nar-ratives in which biobanks have paved the road towards a better tomorrow. Accomplishments in biomarker discovery, community engagement, and advancements in artificial intelligence will be some of the storylines highlighted by speakers who have utilized biobanks for their research.

BIODIVERSITY ARCHIVES AS DATABANKS OF ECOSYSTEMS PAST

Kyle Van Houtan, Monterey Bay Aquarium, USA

Our ability to monitor the status and trends of the ocean is driven by a vast observation network of satellites, buoys, and other sensors and platforms. Though these technologies are rapidly expanding, many robust and decades-long instrument records exist for several key ocean variables. However, for marine systems in particular, longer records are needed to build more informed baselines of ecosystem health as well as to inform effective management decisions. Where can we find such valuable information? In this seminar, I will demonstrate how natural history repositories and museum collections may provide hopeful answers. I will describe how the tissues of most organ-isms contain a memory of their ecosystem experience and will discuss the methods used to extract and generate environmental and population data.

MAKING SCIENCE MATTER: LESSONS FROM THE FRONTLINE

Lester Russell, National Health Service, United Kingdom

We have a global crisis - we seem to be hearing that more and more often these days. But there really is a pressing crisis in the affordability of spending on health. We are accumulating an ever broader range of ever more expensive therapies to treat an ever wider audience of patients. The rise is exponential.

If we are to have a sustainable and high-quality health system, we need to be able to bring effective therapies to patients more cost effectively and more quickly. And to do so requires that we make the best use of the best science at the bedside and in the home.

Drawing on his work for over 35 years in clinical medicine and with experience of national programmes in the UK and beyond, Lester will use examples from his tenure with three major global IT suppliers to indicate a way forward for health and life sciences in the age of AI, mixed reality and quantum computing.

USING DATA PRIVACY TO EMPOWER HEALTH RESEARCH

Dawn Barry, LunaPBC, USA

Data security breaches and the misuse of consumer data by technology companies continues to raise public and legislative concerns around data privacy, ownership, usage, and the insti-tutional sharing of data. Historical disregard for people’s data privacy, control, transparency in data usage, and value imbalance have long hindered discovery, and seem to only be getting worse. The General Data Protection Regulation (GDPR), harmonizing data privacy regulations across European Union member states, has emerged as the de facto global standard for consumer data. On January 1, 2020, the strictest data privacy law in the U.S., the California Consumer Privacy Act, took effect strengthening consum-er data privacy rights in the country’s most populous state. This talk will explore LunaDNA’s perspective on how increasing consumer privacy can improve medical discovery by giving people a role in discovery, improving representation and diversity in research, and opening up solutions and interventions that go beyond drugs.

OCTOBER

MOVING SCIENCE FORWARD – RESULTS DRIVE VALUE/REPUTATION OF BIOBANKS AND ENHANCE SUSTAINABILITY

Date TBD

Biobanks have become key assets to research and clinical care. Biobanks require financial and operational support from organi-zations, key stakeholders and the community to be sustained. This plenary symposium will highlight scientific success stories that have resulted from the use of fit for purpose biospecimens and data from biobanks to power their findings and translation into practice. Scientific success feeds back to increase the stature and reputation of biobanks as an important infrastructure in discovery research. Lessons learned from this plenary will be specific examples of how scientific success can be leveraged to increase the value/reputation and financial, operational and social sustainability of biobanks.

THE RUSSIAN RADIOBIOLOGICAL HUMAN TISSUE REPOSITORY OF THE SOUTHERN URALS BIOPHYSICS INSTITUTE (SUBI)

Christopher Loffredo, Georgetown University Medical Center, USA

The Russian Radiobiological Human Tissue Repository (RHTR) at the Southern Urals Biophysics Institute in Ozyorsk, Russia, is

14

2020 EDUCATION PROGRAM SERIES

focused on biobanking human biological specimens to support research on cancer and other long-term health consequences of chronic low dose ionizing radiation exposures. As such, it is one of the most unique biorepositories in the world. In this talk, Dr. Christopher Loffredo, a cancer epidemiologist and PI of a long-standing US-Russian cooperative agreement on biorepository science, will describe how two major groups of subjects have been donating biospecimens to the RHTR: >1,100 exposed workers at the Mayak nuclear production facilities, and matched city residents of Ozersk (controls) who were never occupa-tionally exposed to ionizing radiation. RHTR personnel collect tissues, blood, and other biomaterials, which are annotated with demographic, occupational, dosimetry, and medical history information. These high-quality biological materials and data are available to interested scientists worldwide, via the RHTR web site that enables users to browse a real-time catalog of speci-mens and data elements. Examples will be described to illustrate the role of RHTR in facilitating state-of-the-art radiobiological research.

BIOPRESERVATION OF REEF CORALS

Anderson Mayfield, NOAA/University of Miami, USA

Coral reefs the world over are threatened by our changing global climate, as well as more localized anthropogenic impacts. Barring the radical changing of human behavior with respect to curbing carbon emissions, the future of highly thermo-sensitive coral reefs would appear bleak indeed. For marine biologists, this crisis poses a dilemma; do we actively intervene and embark on mitigation and/or restoration efforts without the necessary data in hand to do so with utmost scientific rigor, or do we wait until we have acquired all such information, in which case it may be too late? I pose that the coral reef field is now large enough in terms of human power to achieve both acts simultaneously, with some scientists continuing their conservation-driven coral biology research and others actively preserving reef corals. I will discuss both the state-of-the-art in coral biology research, with a particular emphasis on coral diagnostics (i.e., how we know whether a coral is healthy/resilient or sick). I will then shift gears towards focusing on a non-exhaustive series of mitigation efforts currently at our disposal. These are not limited to 1) moving corals from a compromised environment to a less marginalized one, 2) transplanting corals out of the ocean and into aquaria/husbandry facilities, 3) treating corals with drugs in situ or in aquaria, 4) genetically engineering corals or breeding more en-vironmentally tolerant corals (and later outplanting these “super corals” as part of restoration efforts), 5) modifying reef habitats directly, or simply admitting defeat and cryopreserving coral ge-netic material such that reefs may be reseeded at a (theoretical) point in time in which our oceans stabilize.

BIOBANKING IN LATIN AMERICA: ACHIEVEMENTS, CHALLENGES AND PERSPECTIVES

Antonio Hugo Campos, Rede D’Or Network Hospitals, Brazil

Latin America has seen a development in biobanking over the past 15 years. This development has not been uniform, with varying degrees of success in terms of maturity and sustainability. This presentation aims to provide an overview of the biobanking sector in Latin America, addressing examples of success and the main challenges for sustainable development.

FROM HUMAN TUMOR BIOBANKING TO HUMAN TUMOR 3D-BIOPRINTING: INNOVATING FOR PERSONALIZED MEDICINE IN ONCOLOGY

Date TBD

Nicolas Forraz (CTIBiotech, France)

CTIBiotech is a founding member of the IMODI (Innovative Models against cancer, www.imodi-cancer.org) French cancer research consortium which federates public hospitals, academic groups, biotechs and private pharmaceutical companies with the financial support of the French government. IMODI devel-ops predictive preclinical models for 10 cancer indications with a high level of characterization to detect as early as possible in the development process, the most effective and the most appropri-ated anti-cancer therapies for targeted patient populations.

Since 2013, CTIBiotech operates the unified biobank, with over 50 000 biological samples. Tumors are collected from consent-ing patients and dissociated to isolate each cell types within a given tumor. After sorting, each cell type is amplified prior to constructing a 3D tissue model called a micro-tumor. This 3D model mimics the tumor physiologically and morphologically providing a realistic environment for drug testing. In 2015, CTIBiotech research team introduced a technology breach and initiated a transition towards automation with full 3D bioprinting technologies to make them scalable, competitive and replicable. Using the latest tools in bioengineering, CTIBiotech researchers are now printing cancer tissues in 3D called microtumors. The resulting models can be used for highly significant pre-clinical testing. These microtumors accurately reproduce, in vitro, the interactions between human cancer cells and all other types of cells that form the tumor microenvironment. These models can eventually be used to determine the most effective therapy for each patient in a personalized medicine approach.

VISIT WWW.ISBER.ORG FOR MORE INFORMATION

#QBRS

®

ISBER and the ASCP BOC are pleased to announce a new Qualification in

Biorepository Science (QBRS)!

ISBER and ASCP BOC have combined forces to create a qualification exam for biobankers.

Upon meeting specific educational and experience requirements for the qualification, candidates will be eligible to complete an online examination and, if successful, gain recognition for their knowledge,

skills, and competencies as biobankers in the international community. This new qualification will further advance the field of biorepository science! Biobanks are vital to research and development as

well as clinical fields, and require qualified professionals to obtain high quality results that will be useful in advancing biomedicine.

Eligibility requirements are now available! For more information on requirements, topic outline, reading list, and more, visit: www.isber.org/qualification

Application for this qualification is available online now!

Save theDATE

WE HOPE TO SEE YOU

THERE

www.isber.org